About Athersys
Athersys is a company based in United States founded in 1995. Athersys has raised $74.43 million across 16 funding rounds from investors including HHS, Invesco Mutual Fund and Helios. Athersys operates in a competitive market with competitors including Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
- Headquarter United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Athersys, Inc.
-
Annual Revenue
$5.33 M (USD)-3.43as on Dec 31, 2022
-
Net Profit
-$72.53 M (USD)16.58as on Dec 31, 2022
-
EBITDA
-$75.59 M (USD)11.48as on Dec 31, 2022
-
Total Equity Funding
$74.43 M (USD)
in 16 rounds
-
Latest Funding Round
$7.04 M (USD), Post-IPO
Mar 30, 2020
-
Investors
HHS
& 11 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Athersys
Athersys is a publicly listed company on the OTC with ticker symbol ATHXQ in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Athersys
Unlock access to complete
Unlock access to complete
Funding Insights of Athersys
Athersys has successfully raised a total of $74.43M across 16 strategic funding rounds. The most recent funding activity was a Post-IPO round of $7.04 million completed in March 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Athersys
Athersys has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Invesco Mutual Fund and Helios.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Greenleaf Capital Partners is engaged in investment and business consulting.
|
Locked | Locked | Locked | |
|
Government-backed investments are directed toward healthcare, fintech, and various sectors.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Athersys
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Athersys
Investment portfolio details for Athersys
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Athersys
Detailed financials for Athersys
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Athersys Comparisons
Peer comparison for Athersys
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Athersys
Athersys operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| Locked | Locked | Locked |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Developer of drugs for the treatment of multiple disorders
|
Detailed competitors of Athersys
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Athersys
Complete news archive for Athersys
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Athersys
Athersys was founded in 1995 and raised its 1st funding round 5 years after it was founded.
Athersys is headquartered in United States.
Athersys is a funded company, having raised a total of $74.43M across 16 funding rounds to date.
Annual revenue of Athersys is $5.33M as on Dec 31, 2022.
Athersys engaged in the discovery and development of therapeutic product candidates to treat different cardiovascular, neurological, inflammatory diseases. Its product portfolio includes MultiStem, a stem cell product, which is being developed as a treatment for multiple disease indications such as Ischemic stroke, Acute myocardial infarction, Inflammatory bowel disease. In addition, the Company is developing pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, and narcolepsy or other forms of excessive daytime sleepiness.
Athersys's top competitors include Merck, Roivant Sciences and AbbVie.
Yes, Athersys is publicly traded on OTC under the ticker symbol ATHXQ.
Athersys has 12 investors. Key investors include HHS, Invesco Mutual Fund, Helios, Aspire Capital, and Greenleaf Capital Partners.
The ticker symbol of Athersys is ATHXQ on OTC.